
Lakewood-Amedex starts Phase 2a trial for Nu-3 to treat diabetic foot ulcers with drug-resistant infections
Lakewood-Amedex Biotherapeutics has received all necessary Institutional Review Board approvals and confirmed site readiness to begin its Phase 2a clinical trial of Nu-3, a novel topical gel aimed at treating mildly infected diabetic foot ulcers (iDF...





